ClinicalTrials.gg
WithdrawnNCT01269684HERMESUpdated Feb 24, 2017

Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients

A Phase 4 interventional study of Everolimus in Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Withdrawn at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Why this study was withdrawn
No patient has never been included in the trial

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Aug 2008, registered Oct 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate safety and tolerability of an immediate conversion from Tacrolimus to everolimus in stable renal allograft recipients.

Interest in developing CNI-free regimens using other agents such as the proliferation signal inhibitor everolimus.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • Kidney
  • renal
  • transplantation
  • tacrolimus
  • everolimus
  • stable allograft recipients
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary or secondary renal transplantation in the past 12-36 months.
  • Current therapy consisting of Tacrolimus together with MMF +/-.
  • Moderately impaired renal function

Exclusion criteria

Exclusion criteria

  • Multi-organ recipients or previous transplantation with an organ other than a kidney.
  • Acute rejection episodes in the last 6 months.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    1

    Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml

    Drug: Everolimus

Interventions

  • Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml

    Also known as: Certican

06

What researchers measure

Primary outcomes

  1. Routine safety laboratory

    Time frame: At baseline

  2. Routine safety laboratory

    Time frame: Week 1

  3. Routine safety laboratory

    Time frame: Month 1

  4. Routine safety laboratory

    Time frame: Week 2

  5. Routine safety laboratory

    Time frame: Week 3

  6. Routine safety laboratory

    Time frame: Month 2

  7. Routine safety laboratory

    Time frame: Month 4

  8. Routine safety laboratory

    Time frame: Month 6

Secondary outcomes

  1. renal function

    Time frame: At baseline

  2. renal function

    Time frame: Weeks 1, 2 and 3

  3. renal function

    Time frame: Months 1, 2, 4 and 6

07

Study locations

1 site
  • Novartis Investigative Site
    Zurich, Switzerland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2008 to primary completion in Aug 2008, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2010
First posted
Jan 4, 2011
StartActual
Aug 2008
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Last update
Feb 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01269684
Responsible party
Sponsor
First posted
Jan 4, 2011
Start date
Aug 2008
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Feb 24, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion